<SEC-DOCUMENT>0001214659-22-005111.txt : 20220412
<SEC-HEADER>0001214659-22-005111.hdr.sgml : 20220412
<ACCEPTANCE-DATETIME>20220412100128
ACCESSION NUMBER:		0001214659-22-005111
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220412
DATE AS OF CHANGE:		20220412
EFFECTIVENESS DATE:		20220412

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		22821336

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SERVICE EMPLOYEES INTERNATIONAL UNION
		CENTRAL INDEX KEY:			0001076439
		IRS NUMBER:				360852885

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		1800 MASSACHUSETTS AVE NW
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20036
		BUSINESS PHONE:		202-730-7000

	MAIL ADDRESS:	
		STREET 1:		1800 MASSACHUSETTS AVE NW
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SERVICE EMPLOYEE INTERNATIONAL
		DATE OF NAME CHANGE:	19990107
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>o411225px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Notice of Exempt Solicitation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Name of Registrant: Eli Lilly and Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Name of Person Relying on Exemption: SEIU
Benefit Plans Master Trust<BR>
Address of Person Relying on Exemption: 1800 Massachusetts Avenue, NW, Washington, DC 20036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 12, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dear Fellow Eli Lilly Shareholder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Though companies have a legitimate business interest
in influencing laws and regulations, such activities carry numerous risks. Shareholders should receive full information about policy influence
activities to enable them to assess the risks as well as the adequacy of a company&rsquo;s oversight of them, and to evaluate whether
those activities are in the best interests of long-term shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Eli Lilly and Company (&ldquo;Lilly&rdquo; or the
&ldquo;Company&rdquo;) shareholders can call for greater disclosure of Lilly&rsquo;s direct and indirect lobbying expenditures at the
Company&rsquo;s annual shareholder meeting on May 2, 2022. Item #8 on Lilly&rsquo;s proxy card, &ldquo;Proposal to Publish an Annual Report
Disclosing Lobbying Activities&rdquo; (the &ldquo;Proposal&rdquo;), asks Lilly to disclose policies and procedures governing lobbying,
payments used for direct or indirect lobbying as well as grassroots lobbying communications, membership in and payments to tax-exempt
organizations that write and endorse model legislation, and the board and management&rsquo;s decision-making process for making those
payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lilly claims that it &ldquo;already provides shareholders
with extensive disclosures regarding the company&rsquo;s direct and indirect lobbying activities and expenditures, and information necessary
to assess the consistency of the company&rsquo;s lobbying activities with its expressed goals through existing disclosures.&rdquo;<SUP>1</SUP>
But Lilly falls short on disclosure of state, foreign and some indirect lobbying, information the Proposal requests in order to provide
a complete picture of Lilly&rsquo;s policy influence activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">First, <B>Lilly&rsquo;s
disclosure of its state lobbying on its Political Participation Website<SUP>2</SUP> suffers from several major deficiencies</B>. Not all
states require disclosure of lobbying payments, and Lilly does not provide any disclosure regarding activities in such states. Lilly&rsquo;s
state lobbying potentially appears in more than fifty different places, since Lilly merely links to websites containing state lobbying
filings (and some states maintain separate sites for legislative and executive branch lobbying). Each website requires users to search
for the company of interest, and there is no way to know up front whether Lilly has even lobbied in a particular state. Each of these
state sites must be rechecked periodically to update information. This unwieldy assemblage of links cannot reasonably be characterized
as implementing the Proposal&rsquo;s request for a report disclosing expenditures for state lobbying.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Definitive Proxy Statement, at 73.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> https://www.lilly.com/policies-reports/public-policy-political-participation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: right; width: 100%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Lilly does not even provide
a link to lobbying disclosures for Puerto Rico, where one of Lilly&rsquo;s &ldquo;[m]ajor production sites&rdquo;<SUP>3</SUP> is located.
As of 2018, a Lilly subsidiary made Humalog, its second best-selling medicine,<SUP>4</SUP> in Puerto Rico.<SUP>5</SUP> Lilly is listed
as a lobbying client on the Puerto Rico executive branch and Senate registries.<SUP>6</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Second, <B>Lilly&rsquo;s
disclosures include no information on lobbying done outside the United States</B>, which can create risks relating to the Foreign Corrupt
Practices Act (&ldquo;FCPA&rdquo;).<SUP>7</SUP> In 2012, Lilly settled SEC charges that it violated the FCPA by making improper payments
to government officials in Russia, China, Brazil and Poland.<SUP>8</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, bringing down U.S. drug prices, which
are the highest in the world, is a goal supported by large majorities of both Democrats and Republicans.<SUP>9</SUP> For that reason,
pharmaceutical companies may seek less visible avenues of influence over public policy related to pricing. In addition to lobbying through
trade associations, <B>Lilly appears to engage in indirect lobbying through its relationships with groups that present themselves as patient
advocacy organizations.</B> These relationships are not disclosed on the Political Participation Website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lilly is in the highest corporate donation bracket
for JDRF,<SUP>10</SUP> which funds Type 1 diabetes research and &ldquo;advocate[s] for policies that accelerate access to new therapies.&rdquo;<SUP>11</SUP>
People with Type 1 diabetes depend on insulin,<SUP>12</SUP> and Lilly&rsquo;s insulin products account for 16% of its revenues.<SUP>13</SUP>
JDRF&rsquo;s &ldquo;Insulin Access and Innovation&rdquo; principles<SUP>14</SUP> urge that &ldquo;any solution that ensures people with
T1D have access to the insulin they need does not impede the innovation and development of newer and better insulins.&rdquo; Two of JDRF&rsquo;s
three 2021 advocacy priorities focus on innovation, including &ldquo;[e]nsur[ing] United States regulatory policies provide clear and
reasonable pathways for scientific research and therapy approvals.&rdquo;<SUP>15</SUP> Lilly&rsquo;s 10-K describes aspects of the FDA&rsquo;s
drug approval process that could affect the Company&rsquo;s financial results, including the process for approving biosimilar versions
of insulin products.<SUP>16</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP> Filing on Form 10-K, filed on Mar. 18, 2022, at 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP> Filing on Form 10-K, filed on Mar. 18, 2022, at 44.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP> https://www.federalregister.gov/documents/2018/05/18/2018-10646/foreign-trade-zone-ftz-7-mayaguez-puerto-rico-notification-of-proposed-production-activity-lilly-del</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6</SUP> https://registrodecabilderos.pr.gov/Lobbyist/Details;
https://senado.pr.gov/document_vault/lobbylist_registry/207/Reichard%20&amp;%20Escalera,%20LLC.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7</SUP> <U>See</U>, <U>e.g.</U>, Peter Fritsch and Timothy Mapes,
&ldquo;Seedy Indonesian Saga: Monsanto Pays to Settle Allegations of Bribery, <U>The Asian Wall Street Journal</U>, Apr. 5, 2005</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>8</SUP> https://www.sec.gov/news/press-release/2012-2012-273htm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>9</SUP> https://khn.org/news/article/public-opinion-prescription-drug-prices-democratic-plan/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>10</SUP> https://patientsforaffordabledrugs.org/wp-content/uploads/2021/06/06-28-21_P4AD_HiddenHandReport_V24.pdf,
at 9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>11</SUP> https://www.jdrf.org/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>12</SUP> https://www.cdc.gov/diabetes/basics/what-is-type-1-diabetes.html</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>13</SUP> <U>See</U> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm</A>,
at 44 (adding Humalog, Humulin and Basaglar revenues, hen dividing by 2021 total).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>14</SUP> https://www.jdrf.org/impact/advocacy/insulin-access/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>15</SUP> https://www.jdrf.org/impact/advocacy/agenda/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>16</SUP> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm</A>,
at 8, 13, 26</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">We are not asking for
authority to vote your proxy and no proxy cards will be accepted. Please vote your proxy according to the instructions in Lilly&rsquo;s
proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: right; width: 100%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lilly also supports the Alliance for Patient Access
(&ldquo;APA&rdquo;), a 501(c)(4) or &ldquo;social welfare&rdquo; group that Lilly has joined as an associate member.<SUP>17</SUP> All
but two of APA&rsquo;s 32 associate members are pharmaceutical or biotechnology companies.<SUP>18</SUP> Although APA describes its mission
as defending the primacy of the &ldquo;physician-patient relationship&rdquo;<SUP>19</SUP> in treatment decision making, some of its activities
involve pushing back against regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For example, APA has highlighted the &ldquo;dangers&rdquo;
of &ldquo;bad drug&rdquo; advertising-advertising that allegedly overemphasizes potential side effects-targeting newer and pricier classes
of diabetes drugs. Lilly&rsquo;s drug Trulicity falls into one of those classes. APA encouraged physicians to &ldquo;support efforts to
enhance regulations on &lsquo;bad drug&rsquo; advertising by writing to their state legislators and members of Congress.&rdquo;<SUP>20</SUP>
Such efforts could help Lilly, which recently received a letter from the FDA&rsquo;s Office of Prescription Drug Promotion (&ldquo;OPDP&rdquo;)
instructing Lilly to discontinue using a social media post that downplayed side effects and failed to note limitations on Trulicity&rsquo;s
use; the letter noted that the OPDP had communicated with Lilly four times about its promotion of the drug starting in 2014.<SUP>21</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">APA&rsquo;s lobbying and
use of &ldquo;patient access&rdquo; language have spurred negative publicity. A 2019 article spotlighted APA&rsquo;s ties to drug makers
and its sponsorship of an advertisement opposing a proposal to lower drug prices.<SUP>22</SUP> A <U>Washington Post</U> article on the
advertisement called APA an example of an organization engaged in &ldquo;astroturfing,&rdquo; which is <FONT STYLE="color: #303336; background-color: white">&ldquo;activity
that is intended to create a false impression of a widespread, spontaneously arising, grassroots movement in support of or in opposition
to something (such as a political policy) but that is in reality initiated and controlled by a concealed group or organization (such as
a corporation)</FONT>.&rdquo;<SUP>23</SUP> Botched astroturfing campaigns have embarrassed companies and even, in one recent example, led
to fines for vendors executing the campaign.<SUP>24</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Corporate reputation can
translate into financial consequences. Estimates peg the value of corporate reputation at over one-third of market capitalization<SUP>25
</SUP>and one researcher concluded that reputation drives between three and 7.5% of annual revenues.<SUP>26&nbsp;</SUP>According to the
Reputation Institute, a one-point increase in overall reputation score is correlated with a 2.6% increase in share value.<SUP>27</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>_____________________________</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>17</SUP> https://admin.allianceforpatientaccess.org/wp-content/uploads/2022/01/AfPADonorsJanuary2022.pdf;
https://allianceforpatientaccess.org/about</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>18</SUP> https://admin.allianceforpatientaccess.org/wp-content/uploads/2022/01/AfPADonorsJanuary2022.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>19</SUP> <U>See</U> https://allianceforpatientaccess.org/about#membership</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>20</SUP> https://static1.squarespace.com/static/5adfaa0755b02c9316fa91b4/t/60522ec3414ef14cd0a59498/1615998660110/PPPH_Dr.+Lavernia+Q%26A_March+2021.pdf;
<U>see also</U> https://static1.squarespace.com/static/5adfaa0755b02c9316fa91b4/t/609170b327854b67eb83cbbf/1620144308758/PPPH_ChloeOnePager_May2021.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>21</SUP> https://www.fda.gov/media/155627/download</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>22</SUP> https://www.nbcwashington.com/news/national-international/alliance-for-patient-access-pharmaceutical-industry-lobby-drug-prices/87268/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>23</SUP> https://www.merriam-webster.com/dictionary/astroturfing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>24</SUP> <U>See</U> https://ag.ny.gov/sites/default/files/oag-fakecommentsreport.pdf,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>25</SUP> &ldquo;The 2018 U.K. Reputation
Dividend Report,&rdquo; at 1 (http://reputationdividend.com/files/6215/1939/6597/UK_2018_report_Final.pdf); https://mumbrella.com.au/new-research-finds-strong-corporate-reputation-helps-companies-weather-financial-storms-587354</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>26</SUP> <U>See</U> https://instituteforpr.org/reputation/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>27</SUP> https://www.reputationinstitute.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">We are not asking for
authority to vote your proxy and no proxy cards will be accepted. Please vote your proxy according to the instructions in Lilly&rsquo;s
proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: right; width: 100%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">For the reasons discussed
above, we urge you to vote FOR Item #8 on Lilly&rsquo;s proxy card. If you have any questions, pleas<FONT STYLE="font-size: 10pt">e contact
Renaye Manley via email at renaye.manley@seiu.org.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">We are not asking for
authority to vote your proxy and no proxy cards will be accepted. Please vote your proxy according to the instructions in Lilly&rsquo;s
proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
